Target intelligence / Profile preview

Tight junction protein claudin-1 (CLDN1)

Target
CLDN1
Molecular classification
Tight junction protein, Transmembrane protein, Cell adhesion molecule, Other (integral membrane protein, belongs to claudin family)
01

Overview

Tight junction protein claudin-1 (CLDN1) is a transmembrane protein belonging to the claudin family, which are essential components of tight junctions in epithelial and endothelial cells[1][2][4]. Claudin-1 consists of four transmembrane domains, two extracellular loops, and cytoplasmic N- and C-termini, with its C-terminus containing a PDZ domain-binding motif for interactions with scaffolding proteins like ZO-1[1][4]. CLDN1 plays a critical role in regulating paracellular barrier permeability, maintaining cell–cell adhesion, tissue homeostasis, and modulating signaling pathways relevant to cell growth and differentiation[1][4]. Its deregulated expression is a hallmark in several cancers, where it acts as either a tumor promoter or suppressor depending on context, affects metastasis, and is under investigation as a therapeutic target[2]. It is also significant in infection biology, as it serves as a co-receptor for hepatitis C virus entry. Drugs targeting claudin-1 or its complexes modulate tight junction function, with recent research focusing on specificity and safety of such agents for barrier reinforcement, cancer therapy, or antiviral strategies[3][4].

Other names
Claudin-1CLDN1Tight junction protein 1
02

Mechanism of action

Direct disruption or modulation of tight junctions; Induced change in paracellular permeability/barrier function[3]; Blocking viral entry (e.g., HCV)[2]

03

Biological functions

Regulation of paracellular permeabilityMaintenance of epithelial and endothelial barrierCell growth and differentiationCell-cell adhesionTissue homeostasis
04

Disease associations

Cancer (tumor promotion or suppression depending on tissue type)Infection (notably hepatitis C virus entry receptor)InflammationOther (involvement in various barrier-related pathologies)
05

Safety considerations

Potential off-target opening of epithelial/endothelial barriers (leading to loss of tissue integrity, increased risk of infection, and systemic inflammation)[3]Risk of non-selective toxicity if broadly disrupting tight junctions
06

Interacting drugs

COP-1 (claudin-binding tight junction modulator)[3]

2 more in the full profile.

07

Biomarkers

Expression levels of claudin-1 as prognostic or diagnostic marker for cancer subtype, tumor aggressiveness, or metastatic potential[2]Tissue-specific CLDN1 expression used in cancer histopathology

Beyond the preview

Go deeper on Tight junction protein claudin-1 (CLDN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tight junction protein claudin-1 (CLDN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call